Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in metastatic or recurrent malignant melanoma
NCT00243061Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cediranib in Malignant Melanoma (MM), sponsored by National Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
cediranib
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00243061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243061.